[1]CurrentPatentAssignee:ASTRAZENECAPLC-WO2009/133389,2009,A1Locationinpatent:Page/Pagecolumn29
[2]Ball,Matthew;Jones,MartinF.;Kenley,Fiona;Pittam,J.David[OrganicProcessResearchandDevelopment,2017,vol.21,#3,p.310-316]
[3]CurrentPatentAssignee:JANETKAJAMESWALTER;ASTRAZENECAPLC-WO2005/66163,2005,A2Locationinpatent:Page/Pagecolumn67
[1]CurrentPatentAssignee:ASTRAZENECAPLC-WO2009/133389,2009,A1Locationinpatent:Page/Pagecolumn30-31
[1]CurrentPatentAssignee:ASTRAZENECAPLC-WO2009/133389,2009,A1Locationinpatent:Page/Pagecolumn31-32
[1]Ball,Matthew;Jones,MartinF.;Kenley,Fiona;Pittam,J.David[OrganicProcessResearchandDevelopment,2017,vol.21,#3,p.310-316]
Title: Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20131001
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
Journal: Molecular cancer therapeutics 20120801
Title: Synthesis and biological evaluation of analogs of the marine alkaloids granulatimide and isogranulatimide.
Journal: European journal of medicinal chemistry 20120801
Title: Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
Journal: Journal of medicinal chemistry 20120614
Title: Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
Journal: Cancer discovery 20120601
Title: Chk'ing p53-deficient breast cancers.
Journal: The Journal of clinical investigation 20120402
Title: Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Journal: The Journal of clinical investigation 20120402
Title: Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype.
Journal: Cancer biology & therapy 20120301
Title: Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.
Journal: Cancer research 20120215
Title: Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Journal: Cell cycle (Georgetown, Tex.) 20111215
Title: Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.
Journal: Blood 20111110
Title: Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.
Journal: International journal of cancer 20111015
Title: Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition.
Journal: Cell cycle (Georgetown, Tex.) 20111015
Title: Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906.
Journal: The Biochemical journal 20110701
Title: Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110601
Title: Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
Journal: Journal of medicinal chemistry 20110414
Title: Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.
Journal: Nature chemical biology 20110413
Title: Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy.
Journal: Biochemical and biophysical research communications 20110304
Title: Bayesian hierarchical changepoint methods in modeling the tumor growth profiles in xenograft experiments.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110301
Title: Structure-specific DNA endonuclease Mus81/Eme1 generates DNA damage caused by Chk1 inactivation.
Journal: PloS one 20110101
Title: Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.
Journal: Molecular pharmacology 20101101
Title: Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
Journal: Cancer chemotherapy and pharmacology 20100701
Title: Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors.
Journal: Journal of molecular modeling 20100701
Title: Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Journal: Cancer research 20100615
Title: In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100401
Title: Targeting Chk1 in the replicative stress response.
Journal: Cell cycle (Georgetown, Tex.) 20100315
Title: Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
Journal: Cell cycle (Georgetown, Tex.) 20100301
Title: Cell cycle kinases as therapeutic targets for cancer.
Journal: Nature reviews. Drug discovery 20090701
Title: AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Journal: Molecular cancer therapeutics 20080901
Title: Zabludoff SD, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008 Sep;7(9):2955-66.
Title: Quin J, et al. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. Oncotarget. 2016 Aug 2;7(31):49800-49818.
